Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study
David Qualls(Memorial Sloan Kettering Cancer Center), Connie Lee Batlevi(Memorial Sloan Kettering Cancer Center), Kami J. Maddocks(The Ohio State University), Phuong Dao(Memorial Sloan Kettering Cancer Center), Venkatraman Seshan(Memorial Sloan Kettering Cancer Center), Michael J. Buege(Memorial Sloan Kettering Cancer Center), Mwanasha H. Merrill(Dana-Farber Cancer Institute), David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Michelle Okwali(Memorial Sloan Kettering Cancer Center), Brad S. Kahl(UW Health University Hospital), Jason T. Romancik(Emory University), Graham T. Wehmeyer(Cornell University), Behzad Amoozgar(Washington University in St. Louis), Gilles Salles(Memorial Sloan Kettering Cancer Center), Jennifer L. Crombie(Dana-Farber Cancer Institute), Lori A. Leslie(Hackensack University Medical Center), Sarah C. Rutherford(NewYork–Presbyterian Hospital), Paolo F. Caimi(University Hospitals Seidman Cancer Center)
Cited by 20
Related Papers
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
|Advances in Therapy|2017|603